Gene

Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg (CRSP)

admin1 week ago026 mins

RomoloTavani Investment Overview Crispr Therapeutics AG (NASDAQ:CRSP), the first company to secure U.S. approval for a CRISPR (“clustered, regularly interspaced, short palindromic repeats”) based gene editing therapy, Casgevy, indicated for Sickle Cell Disease (“SCD”) and Transfusion Dependent Beta Thalassemia (“TDT”), reported its Q1 2024 earnings yesterday after the bell. The reality is that Crispr Therapeutics…

Rocket Pharmaceuticals’ Promising Path In Gene Therapy (NASDAQ:RCKT)

admin3 months ago010 mins

ktsimage Strategic Acceleration: Rocket Pharmaceuticals’ RP-A501 For Danon Disease Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stock is up 76% since my “Buy” recommendation in August. The stock shot up in September on the heels of a public offering and some other news. Interestingly, the FDA and Rocket reached an agreement supporting the potential for accelerated approval based…

Crispr Therapeutics Stock: I’m Not Betting Against Gene Editing This Time (Upgrade) (CRSP)

admin3 months ago07 mins

Natali_Mis I downgraded CRISPR Therapeutics AG (NASDAQ:CRSP) stock before the official approval of Casgevy by the US FDA in December 2023. Crispr billed the FDA approval as “historic, not only for biomedicine but for humanity as a whole.” As a result, it has opened up new healthcare opportunities in gene editing as a platform, even…

Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry (CRSP)

admin4 months ago020 mins

Bill Oxford CASGEVY approval CASGEVY is a groundbreaking gene therapy, owned by CRISPR Therapeutics AG (CRSP) and Vertex (VRTX) specifically designed for the treatment of sickle cell disease (SCD) in individuals aged 12 and older who experience frequent vaso-occlusive crises (VOCs). Developed through a collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics, CASGEVY stands out as…

CRISPR Gene Editing: Beam Therapeutics

admin6 months ago017 mins

Andy/iStock via Getty Images In my third edition of my CRISPR series (see article 1 (an overview of CRISPR-Cas9) and article 2 (a comparison of CRSP and NTLA)), I want to focus on Beam Therapeutics (NASDAQ:BEAM), which is a favorite amongst investors because it uses what many believe to be a better version of gene…

CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big

admin6 months ago016 mins

Natali_Mis Gene editing, also known as genome editing, is a method where the DNA of an organism is modified using biotechnological techniques. It allows scientists to add, remove, or alter genetic material at particular locations in the genome. This 2-part series will cover the basics of CRISPR-Cas9 (see below) in part 1 and the major…

Taysha Gene Therapies, Inc. (TSHA) Q3 2023 Earnings Call Transcript

admin6 months ago0101 mins

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2023 Results Conference Call November 14, 2023 4:30 PM ET Company Participants Hayleigh Collins – Director and Head of Corporate Communications Sean Nolan – Chief Executive Officer Sukumar Nagendran – President and Head of Research and Development Kamran Alam – Chief Financial Officer Conference Call Participants Whitney Ijem –…

Gene Therapy Breakthroughs On The Horizon

admin9 months ago04 mins

metamorworks In our constant endeavor to find companies ready to launch products and services in the gene therapy space, we come across Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP), which, alongside bluebird bio (BLUE), are penning a new chapter in the story of gene therapy for sickle cell disease. Now, to bring this into context,…

Taysha Gene Therapies: Rett Syndrome Data Makes This A Must Watch (NASDAQ:TSHA)

admin9 months ago015 mins

nuttapong punna/iStock via Getty Images Taysha Gene Therapies (NASDAQ:TSHA) has made great progress recently in advancing its gene therapy known as TSHA-102 for the treatment of patients with Rett Syndrome. Despite only having data from one patient so far, with a second expected to start dosing in Q3 of 2023, the data shown thus far…

StoneX Group: A Long-Term Compounding Machine (NASDAQ:SNEX)

Enbridge: Preferred Shares Most Resilient In Bond Bear Market (OTCMKTS:EBBGF)

Albertsons May Be Win-Win Proposition, With Or Without Kroger Deal (NYSE:ACI)

Philip Morris: Long-Term Looks Good, Short-Term Upside Exhausted (NYSE:PM)

CSQ: Impressive Track Record But Not Impressively Priced (NASDAQ:CSQ)

Gladstone Investment: Drop in Dividend Coverage Not A Reason To Sell (NASDAQ:GAIN)

Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg (CRSP)

Rocket Pharmaceuticals’ Promising Path In Gene Therapy (NASDAQ:RCKT)

Crispr Therapeutics Stock: I’m Not Betting Against Gene Editing This Time (Upgrade) (CRSP)

Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry (CRSP)

CRISPR Gene Editing: Beam Therapeutics

CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big

Taysha Gene Therapies, Inc. (TSHA) Q3 2023 Earnings Call Transcript

Gene Therapy Breakthroughs On The Horizon

Taysha Gene Therapies: Rett Syndrome Data Makes This A Must Watch (NASDAQ:TSHA)